Cognition Therapeutics (CGTX) Revenue & Revenue Breakdown
Cognition Therapeutics Revenue Highlights
Cognition Therapeutics Revenue by Period
Cognition Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Cognition Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Cognition Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $372.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Cognition Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Cognition Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TCRX | TScan Therapeutics | $21.05M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| AUTL | Autolus Therapeutics | $1.70M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| GANX | Gain Therapeutics | $55.18K | - |
| EYEN | Eyenovia | $3.79K | $4.99K |
| CGEM | Cullinan Oncology | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| INAB | IN8bio | - | - |
| CGTX | Cognition Therapeutics | - | - |
| DRMA | Dermata Therapeutics | - | - |
| KOD | Kodiak Sciences | - | - |
| LTRN | Lantern Pharma | - | - |
| RNAZ | TransCode Therapeutics | - | - |
CGTX Revenue FAQ
What is Cognition Therapeutics’s yearly revenue?
Cognition Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CGTX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Cognition Therapeutics’s quarterly revenue?
Cognition Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). CGTX's quarterly revenue for Q4 2023 was $372K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Cognition Therapeutics’s revenue growth rate?
Cognition Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.